Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HUMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHumacyte regains Nasdaq compliance after stock recovers above $1 minimum bid price
Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
medium
Nasdaq notified Humacyte on June 5, 2026 that it has regained compliance with the $1.00 minimum bid price requirement after the stock closed at or above $1.00 for 10 consecutive business days, resolving a prior deficiency.
Item 3.01 view on EDGAR → -
medium
The company had previously received a deficiency notice after its stock traded below $1.00 for 30 consecutive business days ending May 1, 2026, putting its Nasdaq Global Select Market listing at risk.
8-K: Nasdaq Compliance view on EDGAR →
Summary
Humacyte has successfully resolved a Nasdaq listing compliance issue that threatened its exchange status. After falling below the required $1.00 minimum bid price for an extended period through early May 2026, the company's stock recovered and maintained a price at or above $1.00 for the required 10 consecutive trading days. Nasdaq has formally closed the matter, removing the immediate delisting risk.
For retail investors, this is positive news that eliminates near-term uncertainty about the stock's exchange listing. However, the fact that Humacyte's stock fell below $1.00 in the first place signals underlying weakness or investor concerns about the company's prospects. While the immediate compliance crisis is resolved, shareholders should monitor whether the stock can maintain its price above $1.00 and watch for any fundamental business developments that could drive sustained value creation beyond just meeting minimum listing requirements.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 5, 2026, the Company received a letter from the staff of Nasdaq notifying the Company that it had regained compliance with the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a) (1) and that Nasdaq considers the matter closed.
Humacyte received formal notification from Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement for continued listing on the Nasdaq Global Select Market. The company's stock had previously fallen below this threshold for 30 consecutive business days ending May 1, 2026, triggering a deficiency notice. The stock has now closed at or above $1.00 for the required 10 consecutive business days, resolving the listing concern.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify